Through the first nine months of the year, global Johnson and Johnson’s Spravato Ketamine nasal-spray revenues were $483 million, an 88.8% increase over the same period in 2022.

Myth No. 1: Ketamine is a new treatment

Myth No. 2: Ketamine is powerfully addictive

Myth No 3: Ketamine can be self-prescribed and purchased online

Myth No. 4: Intranasal or micro-dosing is safe for recreational use

Myth No. 5: It’s hard to kick the habit

When ketamine becomes dangerous

Read the full article on Fox News: 5 myths about ketamine, the drug tied to Matthew Perry’s death, according to doctors

Related: FDA Approves JNJ’s Ketamine Like Spravato®

Related: Spravato® Sales through the first nine months of the year, globally revenue were $483 million, an 88.8% increase over the same period in 2022.

Related: October 04, 2023, Treatment-resistant depression patients taking Johnson & Johnson’s SPRAVATO® (esketamine) were 1.54 times as likely to reach remission after eight weeks versus Cheplapharm’s Seroquel.

All Spravato® Headlines

Related: Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc. (BWVI) a Topical Ketamine Research Company.

About Treatment-Resistant Depression

Depression is a common mental disorder that impacts an estimated 280 million people worldwide. In the U.S., approximately 21 million adults have had at least one major depressive episode.

RELATED ARTICLESMORE FROM AUTHOR